Oppenheimer Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on ORIC Pharmaceuticals and raises the price target from $14 to $17.
March 12, 2024 | 4:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on ORIC Pharmaceuticals and raises the price target from $14 to $17.
The increase in price target by a reputable analyst suggests a positive outlook on ORIC Pharmaceuticals' stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100